IRIS
PORTA, CAMILLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.685
AS - Asia 5.585
EU - Europa 3.370
SA - Sud America 707
Continente sconosciuto - Info sul continente non disponibili 284
AF - Africa 210
OC - Oceania 15
Totale 17.856
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.473
CN - Cina 2.528
SG - Singapore 1.297
IE - Irlanda 1.171
HK - Hong Kong 614
VN - Vietnam 545
RU - Federazione Russa 510
BR - Brasile 497
FI - Finlandia 341
DE - Germania 310
FR - Francia 251
IT - Italia 178
IN - India 127
UA - Ucraina 127
GB - Regno Unito 125
SE - Svezia 105
CA - Canada 100
ZA - Sudafrica 92
BD - Bangladesh 83
AR - Argentina 80
MX - Messico 57
IQ - Iraq 54
PL - Polonia 47
JP - Giappone 46
NL - Olanda 44
TR - Turchia 43
ES - Italia 37
PK - Pakistan 29
CO - Colombia 28
EC - Ecuador 27
SA - Arabia Saudita 24
ID - Indonesia 22
MA - Marocco 22
MY - Malesia 20
PH - Filippine 20
TN - Tunisia 20
VE - Venezuela 20
AT - Austria 19
UZ - Uzbekistan 19
CL - Cile 15
CZ - Repubblica Ceca 15
LT - Lituania 15
PY - Paraguay 15
EG - Egitto 13
KE - Kenya 13
JO - Giordania 12
BE - Belgio 11
IL - Israele 11
MU - Mauritius 11
AU - Australia 10
NP - Nepal 10
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 9
KZ - Kazakistan 9
PE - Perù 9
UY - Uruguay 9
CR - Costa Rica 8
ET - Etiopia 7
GT - Guatemala 7
HN - Honduras 7
PS - Palestinian Territory 7
PT - Portogallo 7
BG - Bulgaria 6
DZ - Algeria 6
GR - Grecia 6
IR - Iran 6
JM - Giamaica 6
OM - Oman 6
AL - Albania 5
BO - Bolivia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
HU - Ungheria 5
LB - Libano 5
LV - Lettonia 5
BB - Barbados 4
KG - Kirghizistan 4
MD - Moldavia 4
PA - Panama 4
SN - Senegal 4
AO - Angola 3
GA - Gabon 3
HR - Croazia 3
MN - Mongolia 3
NI - Nicaragua 3
RE - Reunion 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
CH - Svizzera 2
CM - Camerun 2
DM - Dominica 2
EE - Estonia 2
EU - Europa 2
IS - Islanda 2
KH - Cambogia 2
KN - Saint Kitts e Nevis 2
LK - Sri Lanka 2
MM - Myanmar 2
Totale 17.529
Salva come PNG Salva come JPEG
Città #
Dublin 1.171
San Jose 1.065
Chandler 870
Ashburn 813
Beijing 650
Hong Kong 601
Singapore 592
Dallas 532
Nanjing 382
Boardman 257
Council Bluffs 234
Princeton 230
Los Angeles 228
Lawrence 222
Helsinki 218
Lauterbourg 187
Jacksonville 169
Medford 167
Wilmington 165
Ho Chi Minh City 160
Nanchang 157
New York 137
Hanoi 131
Shanghai 113
Munich 107
Jiaxing 106
Changsha 101
Hangzhou 95
Shenyang 92
Hebei 91
Buffalo 88
Moscow 84
Redondo Beach 84
Johannesburg 74
Ann Arbor 64
Santa Clara 64
Tianjin 59
Orem 55
Chicago 46
São Paulo 46
Toronto 42
Tokyo 40
Dearborn 39
Turku 39
Warsaw 39
Da Nang 38
Atlanta 37
Norwalk 36
Pavia 36
Chennai 33
Brooklyn 31
London 31
The Dalles 31
Denver 28
Boston 26
Guangzhou 25
Fairfield 24
San Francisco 24
Frankfurt am Main 23
Montreal 23
Stockholm 23
Amsterdam 22
Mexico City 21
Zhengzhou 21
Baghdad 20
Haiphong 20
Washington 20
Columbus 19
Woodbridge 19
Manchester 18
Phoenix 18
Tashkent 18
Falkenstein 17
Nuremberg 17
Poplar 17
Redwood City 17
Jinan 16
Piscataway 16
Seattle 16
Istanbul 15
Houston 14
Kunming 14
Rio de Janeiro 14
Ankara 13
Milan 13
New Delhi 13
Bari 12
Belo Horizonte 12
Ningbo 12
Vienna 12
Amman 11
Brussels 11
Buenos Aires 11
Nairobi 11
Porto Alegre 11
Brasília 10
Des Moines 10
Jeddah 10
Mumbai 10
Padua 10
Totale 11.956
Salva come PNG Salva come JPEG
Nome #
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 160
Allopurinol Mouthwashes In Methotrexate-induced Stomatitis 148
[Eosinophilic infiltration of the gastrointestinal system: description of a clinical case simulating a lymphoproliferative process] 141
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 138
Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. 137
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 137
Case report: long-lasting response in a patient with metastatic renal cell cancer receiving antitumor cytotoxic T lymphocytes 136
Analysis of TERRA expression in Head and Neck Tumors. 133
Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. 132
Lingual metastasis from renal cell carcinoma: a case report and literature review. 130
Osteonecrosis of the Jaw in Patients with Metastatic Renal Cell Cancer Treated with Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature 130
Orai1 and Transient Receptor Potential channels as novel molecular targets to impair tumor neovascularisation in renal cell carcinoma and other malignancies 128
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study 128
Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. 126
Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis 122
Analysis of TERRA expression in Head and Neck Tumors. 119
Circulating endothelial progenitor cells from patients with renal cell carcinoma display aberrant VEGF regulation, reduced apoptosis and altered ultrastructure 119
[Hypokalemic rhabdomyolysis and thiazide diuretics. 3 clinical cases] 119
Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth 119
5-methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo. A phase II study in patients with advanced colon cancer 119
Antiproliferative and cytokinetic effects of the specific Akt inhibitor perifosine on different solid tumor cell lines. 118
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 118
Acute Kidney Injury in Cancer Patients 116
Acute promyelocytic leukaemia (APL): chemotherapy or bone marrow transplantation? 116
Ultrastructural and functional differences between normal and tumor endothelial progenitor cells 115
Endoplasmic reticulum Ca2+ handling and apoptotic resistance in tumor-derived endothelial colony forming cells 115
Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma 115
Catheter seeding of hepatocellular carcinoma following placement of a total implantable access port system 114
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib 111
Telomeric repeat-containing RNAs (TERRA) decrease in squamous cell carcinoma of the head and neck is associated with worsened clinical outcome 110
Amifostine (WR-2721, Ethyol(TM)) can protect human endothelial but not tumor cells from cisplatin-induced cytotoxicity 109
Breast and renal cancer—Derived endothelial colony forming cells share a common gene signature 107
Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. 107
Store-operated Ca2+ entry is over-expressed in endothelial colony forming cells isolated from patients suffering of Renal Cellular Carcinoma. 107
Sarcoidosis following beta-interferon therapy for multiple myeloma 106
Cisplatin, mitomycin-C, 5-fluorouracil and leucovorin combination chemotherapy (l-FCM) in locally advanced unresectable or metastatic gastric carcinoma: a phase-II study 105
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma 105
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 103
[Current approaches to the first-line treatment of clear-cell renal cell carcinoma] 103
Eosinophils and C4 predict clinical failure of combination imunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients 102
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy 102
Autoimmunity in thrombotic thrombocytopenic purpura 101
Concurrent intra-arterial carboplatin administration and radiation therapy for the tretment of advanced head and neck squamous cell carcinima: short term results. 101
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 101
Phenotypic and functional characterization of endothelial progenitor cells isolated from peripheral blood of renal cell carcinoma patients 100
Thrombotic thrombocytopenic purpura resistant to plasma-exchange: salvage treatment with high-dose IgG or vincristine. Italian Cooperative Group for TTP 100
Ocular involvement in acute thrombotic thrombocytopenic purpura 100
Intravenous prostacyclin (as epoprostenol) infusion in thrombotic thrombocytopenic purpura. Four case reports and review of the literature. Italian Cooperative Group for Thrombotic Thrombocytopenic Purpura 100
Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas 99
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 99
Prognostic Value of 18 F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel 99
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? 98
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis 98
Cationic protein-rich supernatants of cultured eosinophils from IL-2-treated patients have no cytotoxic activity on human renal cell carcinoma and melanoma cells: A preliminary report 97
Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP 97
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 97
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial 97
Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes 96
Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients 95
Clinical impact of Pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis 95
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? 95
Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? the experience of Italian centers 95
Store-operated Ca2+ entry is over-expressed in endothelial colony forming cells isolated from tumoral patients; its role in cell proliferation and tubulogenesis 94
[The diagnostic difficulties in a case of Behçet's disease] 94
Nitrite/nitrate balance during photoinduced cerebral ischemia in the rat determined by high-performance liquid chromatography with UV and electrochemical detection 94
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma 94
Cytokinetic and pro-apoptotic effects induced by inhibition of Aurora Kinases: a novel strategy for malignant mesothelioma treatment. 93
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma 93
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer 93
Chronic Epstein-Barr virus infection 93
Thrombotic Thrombocytopenic Purpura In Systemic Lupus-erythematosus 92
Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines 92
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: Final results from an expanded-access trial 92
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises 91
Targeting Stim and Orai proteins as an alternative approach in anticancer therapy 91
Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: possible role in tumor growth 90
Rebuttal to: The usefulness of compression ultrasonography of the lower limbs in patients with a clinical suspicion of pulmonary embolism 90
Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian Cooperative Group for TTP 90
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 90
Impaired bone marrow hematopoietic progenitor cell function in rheumatoid arthritis patients candidated to autologous hematopoietic stem cell transplantation 90
Dovitinib (CHIR258, TKI258): Structure, development and preclinical and clinical activity 89
Chronic myeloid leukemia following cyclophosphamide-containing chemotherapy in a breast cancer patient 89
Targeting angiogenesis in metastatic renal cell carcinoma 89
Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients 88
Editorial Comment from Dr Porta et al. to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA 88
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity? 88
Tivantinib (ARQ197) in hepatocellular carcinoma 88
Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature 88
Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis 88
Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis 87
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents 87
Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP 86
Targeted therapy for renal cell carcinoma: Focus on 2nd and 3rd line 86
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 86
Increased serum lipase with associated normoamylasemia in cancer patients 86
Opening an onconephrology clinic: recommendations and basic requirements 85
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 85
Platelet agonists and calcium homeostasis in endothelial cells: possible role in the interaction of endothelium with hemostatic system 85
Hypocholesterolemia and acute myeloid leukemia (AML) 84
Renal effects of targeted anticancer therapies 84
Totale 10.377
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.008
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.008
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022825 0 0 35 8 18 11 8 56 47 23 152 467
2022/20232.824 363 212 47 175 187 236 1 134 1.350 15 72 32
2023/20241.019 136 189 36 60 92 286 16 58 7 40 59 40
2024/20252.945 88 250 102 62 41 132 77 241 764 107 355 726
2025/20267.207 591 477 869 642 924 290 1.544 310 612 473 265 210
2026/2027543 147 358 38 0 0 0 0 0 0 0 0 0
Totale 17.856